State Street’s Mereo BioPharma MREO Stock Holding History

State Street’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.8K	Buy	134,772 +1,393	+1%	+$418	﹤0.01%	4077
2026 Q1	$44K	Buy	133,379 +2,736	+2%	+$1.17K	﹤0.01%	4147
2025 Q4	$54.4K	Sell	130,643 -2,058	-2%	-$3.92K	﹤0.01%	4139
2025 Q3	$273K	Buy	132,701 +87,759	+195%	+$162K	﹤0.01%	3817
2025 Q2	$122K	Sell	44,942 -717	-2%	-$1.73K	﹤0.01%	3942
2025 Q1	$103K	Sell	45,659 -1,426	-3%	-$4.03K	﹤0.01%	3973
2024 Q4	$165K	Sell	47,085 -476	-1%	-$1.87K	﹤0.01%	3891
2024 Q3	$195K	Buy	+47,561	New	+$197K	﹤0.01%	3829
2022 Q2	–	Sell	-412,768	Closed	-$458K	–	4960
2022 Q1	$458K	Hold	412,768	–	–	﹤0.01%	4088
2021 Q4	$660K	Hold	412,768	–	–	﹤0.01%	3917
2021 Q3	$1M	Buy	412,768 +334,568	+428%	+$886K	﹤0.01%	3781
2021 Q2	$248K	Buy	+78,200	New	+$262K	﹤0.01%	4132
2020 Q1	–	Sell	-16,516	Closed	-$54K	–	3780
2019 Q4	$54K	Hold	16,516	–	–	﹤0.01%	3718
2019 Q3	$48K	Hold	16,516	–	–	﹤0.01%	3723
2019 Q2	$40K	Buy	+16,516	New	+$72.2K	﹤0.01%	3734

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street's MREO Position: Q2 2026 in Review

State Street increased its Mereo BioPharma (MREO) stake by 1% in Q2 2026, buying an estimated $418 and bringing the position to 134,772 shares worth $42.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4077.

State Street first reported a position in MREO in Q2 2019 and has held it in 15 quarters since. The position peaked at $1M in Q3 2021. 61 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

State Street held 134,772 shares of Mereo BioPharma worth $42.8K as of Q2 2026.
State Street bought 1,393 Mereo BioPharma shares in Q2 2026, an estimated $418.
Mereo BioPharma made up ﹤0.01% of State Street's portfolio in Q2 2026, its #4077 holding.
State Street first reported a position in Mereo BioPharma in Q2 2019 and has held it in 15 quarters since.
State Street's Mereo BioPharma position peaked at $1M in Q3 2021.
61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.